Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits

Watch on YouTube ↗  |  January 13, 2026 at 00:48  |  11:33  |  CNBC
Speakers
Mike Doustdar — CEO, Novo Nordisk

Summary

Jim Cramer interviews Novo Nordisk CEO Mike Doustdar at the JPMorgan Healthcare Conference. Doustdar discusses the launch of oral Wegovy, its cardiovascular benefits and weight-loss efficacy, and Novo's pricing strategy to expand access. He also addresses competition from Eli Lilly, criticizes compounded GLP-1 knockoffs, and highlights upcoming rare disease launches including Mim8 for hemophilia and a sickle cell drug.

  • Novo Nordisk CEO Mike Doustdar joins Jim Cramer on Mad Money.
  • Oral Wegovy pill delivers 16.6% weight loss and carries cardiovascular benefits.
  • Novo cuts pricing to $25 with insurance and $149-$249 through partners.
  • Only about 15 million of 100 million U.S. obese patients are on GLP-1.
  • Doustdar says compounded GLP-1 knockoffs are unsafe and should be illegal.
  • Eli Lilly has overtaken Novo but benefited from observing Novo's mistakes.
  • Novo expects rare disease launches including Mim8 and sickle cell by year-end.
Ideas
Mike Doustdar CEO, Novo Nordisk 0:43
Novo's oral Wegovy drives growth.
CEO Mike Doustdar is positive on Novo Nordisk's GLP-1 business, saying it is going very well. The oral Wegovy pill delivers the same 16.6% weight loss as the injectable and carries cardiovascular benefit label because it uses the same semaglutide molecule. Novo is also making the drug more accessible with $25 copay for insured patients and $149-$249 pricing through partners, which should help address the large unmet need.
NVO HIGH
Mike Doustdar CEO, Novo Nordisk 1:20
Oral pill expands GLP-1 obesity market.
The GLP-1 obesity market is underpenetrated. About 100 million people in the U.S. have obesity, but only around 15 million are on GLP-1 therapies, and many of the remaining 85 million are not treated because they cannot afford the drugs. The new oral Wegovy pill can expand the market because it avoids injection, refrigeration, and societal taboo, opening access to a much larger group of patients.
GLP-1 obesity drugs HIGH
Up Next
2:39
Novo Nordisk CEO: People have been waiting for a GLP-1 pill
CNBC · Jan 13
52:03
Secrets of Startup Recruiting in the US AND Japan! (feat. Sho Takei) | E2233
This Week in Startups · Jan 13
2:54:30
[1월13일 #장시작전] 애플 AI모델로 제미나이 채택 '알파벳 시총 4조 달러 돌파' / 한국거래소 6월부터 아침 7시부터 12시간 거래 추진
815 Money Talk (815머니톡) · Jan 13
5:10
Wall Street doesn't care about Trump's credit card plan, 'it is too over the top', says Jim Cramer
CNBC · Jan 13
22:44
트럼프발 변동성, 기회는 늘 소음 뒤에 있다 | 하나증권 빈센트 [두잇나우]
3PRO TV (삼프로TV) · Jan 13

This CNBC video, published January 13, 2026, features Mike Doustdar discussing NVO, GLP-1 obesity drugs. 2 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Mike Doustdar  · Tickers: NVO, GLP-1 obesity drugs